# UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

### 1. Name and Address of Reporting Person

FRAZIER KENNETH C

(4) RAHWAY, NJ 07065

(2)

(3)

(1)

### 2. Issuer Name and Ticker or Trading Symbol

Merck & Co., Inc. [ MRK ]

### 3. Date of Earliest Transaction (MM/DD/YYYY)

11/3/2022

### 4. If Amendment, Date Original Filed (MM/DD/YYYY)

### 5. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

X Form filed by More than One Reporting Person

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security (Instr. 3)</th>
<th>Trans. Date</th>
<th>Trans. Code (Instr. 8)</th>
<th>Amount (A) or (D)</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>11/3/2022</td>
<td>M</td>
<td>235000</td>
<td>$0</td>
</tr>
<tr>
<td>Common Stock</td>
<td>11/3/2022</td>
<td>S</td>
<td>214617</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>11/3/2022</td>
<td>S</td>
<td>20383</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>11/4/2022</td>
<td>M</td>
<td>235000</td>
<td>A</td>
</tr>
<tr>
<td>Common Stock</td>
<td>11/4/2022</td>
<td>S</td>
<td>200190</td>
<td>D</td>
</tr>
</tbody>
</table>

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivate Security (Instr. 3)</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Trans. Date</th>
<th>Trans. Code (Instr. 8)</th>
<th>Date Exercisable</th>
<th>Expiration Date</th>
<th>Title</th>
<th>Amount or Number of Shares</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>$53.06</td>
<td>11/3/2022</td>
<td>M</td>
<td>235000</td>
<td>5/10/2017</td>
<td>D</td>
<td>235000</td>
</tr>
<tr>
<td>Common Stock</td>
<td>$53.06</td>
<td>11/4/2022</td>
<td>M</td>
<td>235000</td>
<td>5/10/2017</td>
<td>D</td>
<td>235000</td>
</tr>
</tbody>
</table>

### Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.0500 to $99.0500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.0600 to $99.2000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.9700 to $98.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.9800 to $99.2800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
Holdings include shares acquired in dividend reinvestment transactions.

Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan.

The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.

### Reporting Owners

<table>
<thead>
<tr>
<th>Reporting Owner Name / Address</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRAZIER KENNETH C MERCK &amp; CO., INC. 126 E. LINCOLN AVENUE RAHWAY, NJ 07065</td>
<td>Director X 10% Owner Officer Executive Chair</td>
</tr>
</tbody>
</table>

**Signatures**

/s/ Kelly E. W. Grez as Attorney-in-Fact for Kenneth C. Frazier 11/7/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.